Katherine Bowdish

Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.

Portal Instruments, Inc. operates as a medical device company that focuses on drug delivery systems. It manufactures jet injectors that deliver drugs through the skin without a needle at specific depths and volumes. The firm engages in developing and commercializing a needle-free platform technology to transform the delivery of medicines and improve the patient experience. The company was founded by Patrick A. Anquetil and Ian W. Hunter in 2012 and is headquartered in Cambridge, MA.

Part of AstraZeneca PLC, Prolifaron, Inc. is a private company that develops antibodies addressing multiple disease areas. The company is based in San Diego, CA. The company was founded by John Randolph Larson, Carlos F. Barbas. Prolifaron was acquired by Alexion Pharmaceuticals, Inc., part of AstraZeneca PLC from July 21, 2021 on September 25, 2000 for $41 million.

Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA.

Alexion Antibody Technologies develops therapeutic antibodies to address multiple diseases.

Thermalin, Inc. engages in the development of insulin products for patients with diabetes. It offers stabilized, ultra-rapid, and highly concentrated; no refrigeration basal and mix; glucose-responsive smart basal; and StampPump insulins. The company was founded by Michael A. Weiss, Bruce H. Frank, and Richard Berenson in 2010 and is headquartered in Cleveland, OH.